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Rationale: Pulmonary rehabilitation is an important treatment for patients with Chronic Obstructive Pulmonary
Disease, who are often vitamin D deficient. As vitamin D status is linked to skeletal muscle function, we aimed to
explore if high dose vitamin D supplementation can improve the outcomes of rehabilitation in Chronic Obstructive
Pulmonary Disease.
Material and methods: This study is a post-hoc subgroup analysis of a larger randomized trial comparing a
monthly dose of 100.000 IU of vitamin D with placebo to reduce exacerbations. 50 Subjects who followed a
rehabilitation program during the trial are included in this analysis. We report changes from baseline in muscle
strength and exercise performance between both study arms after 3 months of rehabilitation.
Results: Vitamin D intervention resulted in significantly higher median vitamin D levels compared to placebo
(51 [44-62] ng/ml vs 15 [13-30] ng/ml; p < 0.001). Patients receiving vitamin D had significantly larger improvements
in inspiratory muscle strength (-11 ± 12 cmH2O vs 0 ± 14 cmH2O; p = 0.004) and maximal oxygen uptake (110 ± 211
ml/min vs -20 ± 187 ml/min; p = 0.029). Improvements in quadriceps strength (15 ± 16 Nm) or six minutes walking
distance (40 ± 55 meter) were not significantly different from the effects in the placebo group (7 ± 19 Nm and
11 ± 74 meter; p > 0.050).
Conclusion: High dose vitamin D supplementation during rehabilitation may have mild additional benefits to
training.
Keywords: Chronic obstructive pulmonary disease, Exercise capacity, Skeletal muscle, Systemic consequences,
Vitamin DIntroduction
Chronic Obstructive Pulmonary Disease (COPD) is cur-
rently appreciated as a complex disease characterized by
pulmonary and extra-pulmonary manifestations [1,2].
Among its co-morbidities or systemic consequences,
skeletal muscle weakness is highly prevalent and one of
the main reasons for referral to pulmonary rehabilitation
[3]. Pulmonary rehabilitation programs have proven
their effect in tackling muscle dysfunction. Resistance* Correspondence: wim.janssens@uzleuven.be.
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reproduction in any medium, provided the ortraining and aerobic training have shown to enhance
skeletal muscle strength, but still a large variability in
training response remains and predictive factors for suc-
cess are poorly understood [4-6].
Vitamin D is essential for maintaining skeletal health
and low vitamin D serum (25-OHD) levels have been
associated with reduced skeletal muscle strength and
increased risk of falls [7-9]. In elderly individuals, vita-
min D status is associated to physical performance and
subsequent functional decline during long-term follow-
up [10]. Randomized trials and meta-analyses in elderly
systematically demonstrate that vitamin D supplementa-
tion improves balance and reduces falls by approxi-
mately 20% [11,12]. Data are less consistent in showingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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According to a recent meta-analysis benefits of supple-
mentation were only present when baseline 25-OHD
levels are very low (<10ng/ml) [13]. Nevertheless, be-
cause large cross-sectional data suggests that muscle
strength continues to increase from 25-OHD levels of
9ng/ml to 37ng/ml [7], it can be speculated that benefi-
cial effects on the muscle are only seen when higher
doses of supplementation are given [14].
Vitamin D deficiency is highly prevalent in COPD and
the prevalence increases with disease severity [15]. Al-
though a direct relationship between 25-OHD levels and
quadriceps function has not been shown in COPD, gen-
etic polymorphisms in the vitamin D receptor (VDR)
have been associated with quadriceps strength [16,17].
Several authors have also linked vitamin D deficiency to
impaired exercise capacity, a higher risk of drop-out
from rehabilitation and a tendency towards reduced
training benefits [17-19]. To our best knowledge, no ran-
domized trials are currently available that have explored
the effect of vitamin D supplementation on top of an ex-
ercise training program in COPD. We hypothesized that
high dose vitamin D supplementation may improve the
outcomes of a pulmonary rehabilitation program in
patients with severe COPD [20].
The present study is an exploratory post-hoc analysis
of a double-blind randomized placebo controlled trial
administering a monthly dose of 100.000 IU of vitamin
D to reduce exacerbations in patients with moderate to
severe COPD over 1 year [21]. As part of their standard
care, a subgroup was willing to participate in a 3 month
rehabilitation program at the moment of randomization.
The current subgroup analysis compares benefits of vita-




The present study is a post-hoc subgroup analysis of a
double blind randomized controlled trial. 182 patients
were randomly allocated to a monthly dose of vitamin D
(100.000 IU) or a placebo and were followed for 1 year. In-
clusion and exclusion criteria, study design and results
have been previously described [21]. Briefly, eligible
patients were current or former smokers, aged above 50
years, with a diagnosis of COPD according to the “Global
Initiative for Chronic Obstructive Lung Disease” definition
(post-bronchodilator Forced Expiratory Volume in one
second (FEV1)/Forced Vital Capacity (FRC) ratio of less
than 0.7) and with an FEV1 of less than 80% of the pre-
dicted value [22]. Patients were excluded if there was a
history of hypercalcaemia, sarcoidosis or active cancer.
Patients were screened during hospitalization for exacer-
bation and randomized 5 to 6 weeks after discharge ifreturned to re-convalescent state. At randomization,
patients were tested in terms of muscle strength, exercise
performance and health-related quality of life. If clinically
indicated (symptoms of dyspnea and one of the following
criteria: maximal workload (Wmax) < 90 watt, six minutes
walking distance (6MWD) < 70% of predicted values,
quadriceps strength (QF) < 70% of predicted values),
patients were informed about outpatient pulmonary re-
habilitation. 50 patients out of 182 patients were willing to
participate in the training program, which started at the
beginning of the trial and continued for at least 3 months.
More specifically, some patients received both vitamin D
(100.000 IU of cholecalciferol) and respiratory rehabilita-
tion whereas others were treated with placebo (4 ml of
arachidis oleum, vehicle) during respiratory rehabilitation.
Changes over 3 months in peripheral and respiratory
muscle strength, functional and maximal exercise capacity
and health-related quality of life were compared between
the placebo and vitamin D arm in this subgroup of 50
patients. Figure 1 provides the consort flow chart. The
study was approved by the Ethics committee of the univer-
sity hospital of Leuven and all subjects signed written
informed consent. The study was registered at clinical-
trials.gov (Clinical Trial Number: NCT00666367).
Pulmonary rehabilitation program
The patients participated in a 3 months outpatient
multidisciplinary rehabilitation program at a frequency
of 3 times a week as previously described [23,24]. During
90 min of training, study subjects had to go through a
circuit of exercises: cycling, walking on the treadmill,
stair climbing, strength exercises for the upper and
lower extremities and arm cranking. The initial training
intensity was set at 60% of the baseline maximal work-
load for cycling and at 75% of the average walking speed
during the baseline six minutes walking distance for
treadmill walking. Physiotherapists increased patients’
workload on a weekly basis, guided by Borg-symptom
scores. A Borg score of 4-6 for dyspnea or fatigue was
set as a target. For the cycling training, the aim was to
achieve 85% of the baseline maximal workload for 16
min, whereas for the treadmill the aim was to achieve
110% of the walking speed of the baseline six minutes
walking distance for 16 min. In the strength training,
patients performed 3 times of 8 repetitions with the ini-
tial load determined as 70% of the one repetition max-
imum (1RM) (the maximum load which can be moved
only once over the full range of motion without com-
pensatory movements). For this modality, the aim was to
increase the load by 3% to 6% of the 1RM per week in
order to achieve 121% of the 1RM at 3 months of train-
ing. Arm cranking was performed in 2-min blocks (1 to
3 sets) with the load set in an individual basis. Stair
climbing was performed in a two-step stairs in which
Figure 1 Flow chart of the study.
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(1 to 3 sets) [23].
Methods
25-OHD level
Blood samples were taken in the fasted state at baseline
prior to the study drug intake and after 3 months. Serum
total 25-OHD was measured in multiple batches by
radioimmunoassay (DiaSorin, Minnesota, USA) in allstudy participants. Total 25-OHD measures are mean
values of duplicate measures referred to appropriate
positive controls. Levels are expressed in ng/ml (conver-
sion factor for nmol/l = 2.5). Vitamin D deficiency was
defined as levels below 20 ng/ml.
Pulmonary function
All subjects performed spirometry (Jaeger Master Screen
Body; CareFusion; Germany) to determine FEV1 and
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mendations [23]. The results are referred to the pre-
dicted values reported by Quanjer et al. [25].
Peripheral muscle strength
Isometric quadriceps strength was measured using a
dynamometer (Biodex system 4 pro; Enraf Nonius; Delft,
The Netherlands). Peak extension torque was measured
at the dominant side, and evaluated at 60° of knee
flexion. After an exercise trial, tests were performed at
least 3 times and the best of 2 reproducible tests was
used for further analyses [23]. Reference values for the
quadriceps strength were developed in our laboratory
[26].
Respiratory muscle strength
Maximal inspiratory (MIP) and expiratory (MEP) pres-
sures were measured according to a modification of the
Black and Hyatt method [27]. The modification con-
sisted in the use of an electronic transducer instead of
an aneroid manometer. Maximal inspiratory pressure
was measured from residual volume, while maximal ex-
piratory pressure was measured from TLC. Tests were
repeated at least 5 times, until 3 attempts differed by
<5% [23]. The highest values were related to the refer-
ence values of Rochester and Arora [28].
Functional exercise capacity
Functional exercise performance was measured by six
minutes walking distance test in a 53-meter corridor.
Encouragement was standardized. The largest distance
of 2 tests was used in the analysis [23], and normal
values were those described by Troosters et al. [29].
Maximal exercise capacity
Maximal exercise capacity was assessed by a symptom-
limited incremental cycle ergometer test (Ergoline 900,
Bitz, Germany). The test was performed according to
the standard of the ATS/ACCP statement on Cardiopul-
monary Exercise Testing [30]. After 3 min of unloaded
cycling, patients started the test with a workload of 20
watts and cycled at an incremental workload of 10 watts
each minute. Peak oxygen consumption, ventilation and
carbon dioxide output were measured breath by breath
(Sensor Medics 6200, Bilthoven, The Netherlands). Heart
rate was monitored continuously by 12 leads electrocar-
diogram [23]. The values of peak oxygen consumption
were related to the normal values by Jones et al. [31].
Health-related quality of life
The Chronic Respiratory Disease Questionnaire (CRDQ)
was used to assess health-related quality of life. This
questionnaire scores quality of life in 4 domains (dys-
pnea, fatigue, emotional functioning, mastery). A totalscore can be obtained by summation of the above men-
tioned domains, with higher scores indicating better
quality of life [23].
Statistical analysis
All statistical analyses were executed with SAS version 9
statistical package (SAS Institute, Cary, North Carolina)
and GraphPad Prism 4 (GraphPad Software, San Diego,
California). A Kolmogorov-Smironov test was executed
to test for normality of the distributions. Data were
expressed as mean ± standard deviation (if data were
normally distributed) or as median [interquartile range;
IQR] (if data were not normally distributed). The level of
significance was set at α = 0.05. Training benefits in the
total population were examined by a paired t-test. The
change in the vitamin D level within each subgroup was
evaluated by a Wilcoxon signed-ranks test. An unpaired
t-test was used to compare the baseline characteristics
of both subgroups and the difference between 3 months
changes between both subgroups.
Results
Baseline characteristics
Table 1 is showing the baseline characteristics of the
subgroup of patients referred for rehabilitation (n = 50)
from the total study population (n = 182), stratified
according to randomization arm. Blood samples are
taken prior to any study drug intake and reflect baseline
25-OHD levels. By chance, of 50 patients referred for re-
habilitation exactly 25 patients were allocated to placebo,
25 patients to vitamin D supplementation and both sub-
groups were matched for all baseline parameters. Quad-
riceps strength and maximal inspiratory muscle strength
tended to be lower in the vitamin D group.
Vitamin D serum level
As expected, the median 25-OHD level significantly
increased within the intervention group from 15 [13-30]
ng/ml at baseline to 51 [44-62] ng/ml after 3 months of
rehabilitation (p < 0.001), whereas the mean 25-OHD
level remained relatively stable in the group receiving
placebo (19 [13-22] ng/ml vs 18 [14-34] ng/ml; p =
0.089) (Figure 2). At baseline, 62% (31/50) of the
patients had a 25-OHD level < 20ng/ml, 16 in the pla-
cebo group and 15 in the Vitamin D arm. After study
drug intake, vitamin D deficiency disappeared in all
patients in the vitamin D arm without any toxicity in
terms of hypercalcaemia or hypercalciuria.
Outcomes of rehabilitation
Total study population
In the total study population conventional rehabilitation
during 3 months resulted in an increased muscle
strength (ΔQF 11 ± 18 Nm, p < 0.001; ΔMIP -5 ± 14
Table 1 Baseline characteristics of patients with COPD referred for rehabilitation
Placebo Vitamin D P-value
(n = 25) (n = 25)
Antropometric data:
Age (years) 69 ± 6 67 ± 8 0.464
Gender (male/female) 19/6 19/6 1.000
BMI (kg/m2) 24 ± 6 25 ± 5 0.587
GOLD Stages 0.492
I (n) 0 2
II (n) 6 7
III (n) 15 12
IV (n) 4 4
Serum vitamin D level:
25-OHD (ng/ml) 20 ± 11 23 ± 15 0.492
Pulmonary function:
FEV1(l) 1.06 ± 0.28 40 ± 10(*) 1.22 ± 0.50 47 ± 18(*) 0.115
FVC (l) 2.85 ± 0.80 83 ± 20(*) 2.96 ± 0.76 89 ± 22(*) 0.328
Muscle function:
QF (Nm) 106 ± 36 83 ± 27(*) 109 ± 41 75 ± 20(*) 0.242
MIP (cmH2O) −77 ± 26 72 ± 20(*) −67 ± 24 63 ± 21(*) 0.107
MEP (cmH2O) 158 ± 55 83 ± 22(*) 152 ± 50 80 ± 26(*) 0.685
Exercise Performance:
6MWD (meter) 422 ± 109 70 ± 19(*) 391 ± 135 65 ± 23(*) 0.435
VO2max (l/min) 1.21 ± 0.48 72 ± 24(*) 1.15 ± 0.43 75 ± 38(*) 0.802
Wmax (watt) 71 ± 27 54 ± 22(*) 67 ± 29 52 ± 25(*) 0.713
Health-Related Quality of Life:
CRDQdyspnea (points) 16.1 ± 4.36 17.3 ± 4.6 0.366
CRDQtotal (points) 82.6 ± 16.0 83.1 ± 17.4 0.721
Data are expressed as mean ± SD. Values are %Pred ± SD when indicated with (*). BMI = Body Mass Index; 25-OHD = Serum vitamin D level; FEV1 = Forced Expiratory
Volume in one second; FVC = Forced Vital Capacity; QF = Quadriceps Strength; MIP = Maximal Inspiratory Pressure; MEP = Maximal Expiratory Pressure; 6MWD = Six
Minutes Walking Distance; VO2max = Maximal Oxygen Uptake; Wmax = Maximal Workload; CRDQdyspnea = Chronic Respiratory Disease Questionnaire (Item Dyspnea);
CRDQtotal = Total score on Chronic Respiratory Disease Questionnaire.
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Maximal exercise capacity tended to improve (ΔWmax
6 ± 13 watt, p = 0.002; ΔVO2max 45 ± 108 ml/min, p =
0.144) and a statistical significant effect was found in
functional exercise capacity (Δ6MWD 25 ± 66 m, p =
0.012). Quality of life scores significantly improved. The
obtained effects in the total score (CRDQtotal) and in the
sub-item for dyspnea (CRDQdyspea) were much larger
than the respective 10 and 2.5 points increase required to
obtain an minimal important clinical benefit (ΔCRDQtotal
15 ± 9.3, p < 0.001; ΔCRDQdyspnea 6.0 ± 4.6, p < 0.001).
Vitamin D group and placebo group
Table 2 and Figure 3 provide an overview of the changes
in muscle strength after 3 months of pulmonary rehabili-
tation when comparing the vitamin arm to the placebo
group. Patients receiving vitamin D had a statisticalsignificantly higher increase in maximal inspiratory
strength. Quadriceps strength and maximal expiratory
strength improved more in the vitamin D group com-
pared to the placebo group, but without reaching statis-
tical significance. The effects were not more pronounced
in vitamin D deficient patients (Table 3).
Table 4 and Figure 4 summarize the changes in exer-
cise performance after 3 months of rehabilitation when
comparing the vitamin D group with the placebo group.
Statistically significant improvements in maximal oxygen
uptake were obtained in the vitamin D group compared
to placebo. Patients receiving vitamin D also improved
more in terms of maximal workload and six minutes
walking distance, but these effects were not statistically
significant. When performing the same analyses in
patients with vitamin D deficiency at baseline (Table 5),
no significant changes could be found. We finally
Figure 3 Changes in muscle strength (QF = Quadriceps
Strength; MIP = Inspiratory Muscle Strength; MEP = Expiratory
Muscle Strength) in the vitamin D group (■) and in the placebo
group (□). Data are expressed as mean ± SD. Baseline results are
compared with results after 3 months of rehabilitation. Results with
p <0.05 are indicated with (*).
Figure 2 Change in 25-OHD (Serum Vitamin D Level) in the
vitamin D group (■) and in the placebo group (□). Data are
expressed as mean ± SD. Baseline results are compared with results
after 3 months of rehabilitation. Results with p <0.05 are indicated
with (*).
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D group and the placebo group. We found no statistical
significant difference, although a positive trend in favor
of the vitamin D group was observed for the dyspnea
item (Δ7.0 ± 5.2 in the vitamin D group vs Δ5.5 ± 3.9 in
the placebo group; p = 0.16)
Discussion
The present study is the first placebo controlled inter-
vention study exploring the effect of supplementation
with high doses of vitamin D in a 3 month rehabilitation
program in patients with COPD. We found that, com-
pared to training alone, patients receiving a monthly
dose of 100.000 IU of vitamin D had a larger improve-
ment on inspiratory muscle strength and peak exercise
tolerance. There was a similar trend towards higher
quadriceps strength, six minutes walking distance and
dyspnea scores, but these effects did not reach statistical
significance.
Although the reported effects are rather limited, the
current data support the hypothesis that vitamin D sup-
plementation may enhance training effects in disabled
patients with muscle weakness and reduced exercise
capacity. There are two reasons which may explain whyTable 2 Changes in peripheral and respiratory muscle
strength in both groups after rehabilitation
Placebo Vit D P-value
(n = 25) (n = 24)
Δ Muscle Function
QF (Nm) 7 ± 19 15 ± 16 0.121
MIP (cmH2O) 0 ± 14 −11 ± 12 0.004
MEP (cmH2O) 6 ± 41 13 ± 35 0.511
Data are expressed as mean ± SD. QF = Quadriceps Strength; MIP = Inspiratory
Muscle Strength; MEP = Expiratory Muscle Strength.a larger and general benefit could not be found. Most
importantly, our data are post-hoc subgroup analyses of
a larger randomized controlled trial and therefore not
designed nor sufficiently powered to demonstrate clinic-
ally significant benefits. Secondly, our training program
in the total study group yielded important effects on
quality of life and symptoms, but resulted in somewhat
smaller effects than expected on physiological outcomes.
As the latter outcomes would be preferentially affected
by vitamin D because of common pathways in the
Table 3 Changes in peripheral and respiratory muscle
strength in vitamin D deficient patients after
rehabilitation
Placebo Vit D P-value
(25-OHD < 20) (25-OHD < 20)
(n = 16) (n = 15)
Δ Muscle Function
QF (Nm) 6 ± 19 15 ± 19 0.176
MIP (cmH2O) 0 ± 16 −9 ± 6 0.046
MEP (cmH2O) 2 ± 44 16 ± 33 0.333
Data are expressed as mean ± SD. QF = Quadriceps Strength; MIP = Inspiratory
Muscle Strength; MEP = Expiratory Muscle Strength.
Figure 4 Changes in exercise performance (6MWD= Six
Minutes Walking Distance; VO2max =Maximal Oxygen Uptake;
Wmax = Maximal Workload) in the vitamin D group (■) and in
the placebo group (□). Data are expressed as mean ± SD. Baseline
results are compared with results after 3 months of rehabilitation.
Results with p <0.05 are indicated with (*).
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D was a priori small. The absence of clinically relevant
training benefits in quadriceps strength and functional
exercise capacity in the total subgroup may reflect the
individual variability in training response, especially
observed in very disabled COPD. Nevertheless, largest
effects were preferentially obtained in the vitamin D
supplemented group, whereas the placebo group seemed
more resistant to physiological improvements.
Currently, it is still unclear which serum vitamin D
levels are needed for an optimal muscle function
[7,14,32]. Different intervention studies indicate that
vitamin D supplementation may only improve muscle
strength when baseline levels are deficient but surpris-
ingly, few studies have explored this question in a con-
text of training [33]. Bunout et al. reported that a daily
intake of 400 IU of vitamin D with 800 mg of calcium
plus biweekly strength, balance and aerobic exercises in
an elderly population did not enhance muscle mass or
function compared to either exercise or vitamin D alone
[34]. A more recent randomized trial evaluated whether
a daily consumption of fortified milk (800 IU of vitamin
D and 1000 mg of calcium) enhanced the effects of re-
sistance training in a community dwelling elderly popu-
lation, but again no significant effect could be found
[35]. Different authors therefore suggested that the sup-
plementation dosage of vitamin D in these trials was
probably insufficient to obtain potential benefits [14,33].
Our data support this idea as the high dose of vitamin DTable 4 Changes in exercise performance in both groups
after rehabilitation
Placebo Vit D P-value
(n = 25) (n = 24)
Δ Exercise Performance
6MWD (meter) 11 ± 74 40 ± 55 0.130
VO2max (ml/min) −20 ± 187 110 ± 211 0.029
Wmax (watt) 3 ± 13 10 ± 13 0.053
Data are expressed as mean ± SD. 6MWD = Six Minutes Walking Distance;
VO2max = Maximal Oxygen Uptake; Wmax = Maximal Workload.(corresponding to a daily intake of 3300 IU) increased
median 25-OHD levels up-to 51 [44-62] ng/ml in the
intervention arm with superior clinical effects compared
to placebo. We also evaluated whether larger benefits
were present in the subgroup of patients being vitamin
D deficient at baseline. No significant relationship could
be found but we should acknowledge that these sub-
groups were probably too small to appreciate any
difference.
Table 5 Changes in exercise performance in vitamin D
deficient patients after rehabilitation
Placebo Vit D P-value
(25-OHD < 20) (25-OHD < 20)
(n = 16) (n = 15)
Δ Exercise Performance
6MWD (meter) 18 ± 45 45 ± 44 0.106
VO2max (ml/min) −8 ± 190 96 ± 202 0.156
Wmax (watt) 3 ± 14 10 ± 12 0.140
Data are expressed as mean ± SD. 6MWD = Six Minutes Walking Distance;
VO2max = Maximal Oxygen Uptake; Wmax = Maximal Workload.
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ther direct on contractility via blood calcium levels, but
most are indirectly mediated through the vitamin D re-
ceptor (VDR) which is abundantly expressed in the skel-
etal muscle [36]. Vitamin D deficiency is shown to
reduce actin and troponin content, to impair calcium
uptake in the sarcoplasmatic reticulum, to down-
regulate protein synthesis and to increase apoptosis
[8,37], processes which are all described in skeletal mus-
cles of patients with COPD [38-40]. Typically, severe
vitamin D deficiency results in a type II fiber atrophy
with interfibrillar spaces infiltrated with fat, fibrocytes
and glycogen [35]. As skeletal muscles of patients with
COPD are characterized by fiber type shifts towards a
type II profile, vitamin D deficiency may have a superim-
posed deleterious effect [37,41]. Since patients with
COPD are often vitamin D deficient and frequently suf-
fer from skeletal muscle weakness, they compose an
interesting target population for combined intervention
studies with vitamin D supplements and training [42].
Currently, a randomized trial specifically designed to
study these questions in COPD is ongoing (clinicaltrials.
gov. NCT01416701). Our data generate aspiration that a
significant and clinical benefit may be revealed.
Overall, the present post-hoc analysis supports the
idea that in patients with COPD high dose supplementa-
tion with vitamin D can be beneficial when combined
with exercise training. Our data should be confirmed by
other studies sufficiently powered to evaluate clinical
and sustained benefits in patients with COPD or specific
subgroups. Only then recommendations on the appro-
priate use and dosage of vitamin D supplements in a
clinical context of training can be made.
Competing interests
The author(s) declare that they have no competing interests.Authors’ contribution
MH, HVR, MD, TT and WJ carried out the rehabilitation program. KM, GGR,
MD, TT and WJ designed the study analysis. AL, CM, MD and WJ designed
and carried out the randomized trial. MH, TT and WJ drafted the manuscript.
All authors read and approved the final manuscript.Support
Grant from the Applied Biomedical Research Program, Agency for Innovation
by Science and Technology (IWT-TBM: G335102)
KM, WJ and CM are supported by the research foundation Flanders (FWO).
MH is funded by the FWO Grant #G.0598.09N.
Author details
1Respiratory Division and Rehabilitation, Laboratory of Pneumology,
University Hospital Gasthuisberg, KULeuven, Herestraat 49, Leuven 3000,
Belgium. 2Division of Endocrinology, University Hospital, KULeuven, Leuven,
Belgium. 3Department of Rehabilitation Sciences, Faculty of Kinesiology and
Rehabilitation Sciences, KULeuven, Leuven, Belgium.
Received: 9 July 2012 Accepted: 18 September 2012
Published: 25 September 2012References
1. Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD.
Eur Respir J 2009, 33:1165–1185.
2. Decramer M, Janssens W, Miravitlles M: Chronic obstructive pulmonary
disease. Lancet 2012, 379:1341–1351.
3. Gosselink R, Troosters T, Decramer M: Peripheral muscle weakness
contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996,
153:976–980.
4. Burtin C, Saey D, Saglam M, Langer D, Gosselink R, Janssens W, Decramer M,
Maltais F, Troosters T: Effectiveness of exercise training in patients with
COPD: the role of muscle fatigue. Eur Respir J 2012, 40:338–344.
5. Casaburi R, ZuWallack R: Pulmonary rehabilitation for management of
chronic obstructive pulmonary disease. N Engl J Med 2009,
360:1329–1335.
6. Troosters T, Gosselink R, Janssens W, Decramer M: Exercise training and
pulmonary rehabilitation: new insights and remaining challenges.
Eur Respir Rev 2010, 19:24–29.
7. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW,
Wson-Hughes B: Higher 25-hydroxyvitamin D concentrations are
associated with better lower-extremity function in both active and
inactive persons aged > or =60 y. Am J Clin Nutr 2004, 80:752–758.
8. Ceglia L: Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr
Metab Care 2009, 12:628–633.
9. Menant JC, Close JC, Delbaere K, Sturnieks DL, Trollor J, Sachdev PS, Brodaty
H, Lord SR: Relationships between serum vitamin D levels,
neuromuscular and neuropsychological function and falls in older men
and women. Osteoporos Int 2012, 23:981–989.
10. Wicherts IS, van Schoor NM, Boeke AJ, Visser M, Deeg DJ, Smit J, Knol DL,
Lips P: Vitamin D status predicts physical performance and its decline in
older persons. J Clin Endocrinol Metab 2007, 92:2058–2065.
11. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B: Effect of cholecalciferol
plus calcium on falling in ambulatory older men and women: a 3-year
randomized controlled trial. Arch Intern Med 2006, 166:424–430.
12. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE,
Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J: Fall prevention with
supplemental and active forms of vitamin D: a meta-analysis of
randomised controlled trials. BMJ 2009, 339:b3692.
13. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL: Effect of
vitamin D supplementation on muscle strength: a systematic review and
meta-analysis. Osteoporos Int 2011, 22:859–871.
14. Dawson-Hughes B: Serum 25-hydroxyvitamin D and muscle atrophy in
the elderly. Proc Nutr Soc 2012, 71:46–49.
15. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I,
Coolen J, Mathieu C, Decramer M, Lambrechts D: Vitamin D deficiency is
highly prevalent in COPD and correlates with variants in the vitamin
D-binding gene. Thorax 2010, 65:215–220.
16. Hopkinson NS, Li KW, Kehoe A, Humphries SE, Roughton M, Moxham J,
Montgomery H, Polkey MI: Vitamin D receptor genotypes influence
quadriceps strength in chronic obstructive pulmonary disease. Am J Clin
Nutr 2008, 87:385–390.
17. Romme EA, Rutten EP, Smeenk FW, Spruit MA, Menheere PP, Wouters EF:
Vitamin D status is associated with bone mineral density and functional
exercise capacity in patients with chronic obstructive pulmonary disease.
Ann Med 2012, Epub ahead of print.
Hornikx et al. Respiratory Research 2012, 13:84 Page 9 of 9
http://respiratory-research.com/content/13/1/8418. Ferrari M, Schenk K, Papadopoulou C, Ferrari P, Dalle CL, Bertoldo F: Serum
25-hydroxy vitamin D and exercise capacity in COPD. Thorax 2011,
66:544–545.
19. Ringbaek T, Martinez G, Durakovic A, Thogersen J, Midjord AK, Jensen JE,
Lange P: Vitamin d status in patients with chronic obstructive pulmonary
disease who participate in pulmonary rehabilitation. J Cardiopulm Rehabil
Prev 2011, 31:261–267.
20. Janssens W, Mathieu C, Boonen S, Decramer M: Vitamin D deficiency and
chronic obstructive pulmonary disease: a vicious circle. Vitam Horm 2011,
86:379–399.
21. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van EJ,
Decallonne B, Bouillon R, Decramer M, Janssens W: High doses of vitamin
D to reduce exacerbations in chronic obstructive pulmonary disease: a
randomized trial. Ann Intern Med 2012, 156:105–114.
22. Globale Initiative for Chronic Obstructive Lung Disease (GOLD): Global
Strategy for the Diagnosis, Management and Prevention of COPD. 2011.
http://www.goldcopd.org.
23. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R: Are
patients with COPD more active after pulmonary rehabilitation? Chest
2008, 134:273–280.
24. Troosters T, Casaburi R, Gosselink R, Decramer M: Pulmonary rehabilitation
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005,
172:19–38.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC:
Lung volumes and forced ventilatory flows. Report working party
standardization of lung function tests, european community for steel
and coal. official statement of the european respiratory society. Eur Respir
J Suppl 1993, 16:5–40.
26. Decramer M, Lacquet LM, Fagard R, Rogiers P: Corticosteroids contribute
to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care
Med 1994, 150:11–16.
27. Black LF, Hyatt RE: Maximal respiratory pressures: normal values and
relationship to age and sex. Am Rev Respir Dis 1969, 99:696–702.
28. Rochester DF, Arora NS: Respiratory muscle failure. Med Clin North Am
1983, 67:573–597.
29. Troosters T, Gosselink R, Decramer M: Six minute walking distance in
healthy elderly subjects. Eur Respir J 1999, 14:270–274.
30. ATS/ACCP: Statement on cardiopulmonary exercise testing. Am J Respir
Crit Care Med 2003, 167:211–277.
31. Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N: Normal
standards for an incremental progressive cycle ergometer test. Am Rev
Respir Dis 1985, 131:700–708.
32. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266–281.
33. Daly RM: Independent and combined effects of exercise and vitamin D
on muscle morphology, function and falls in the elderly. Nutrients 2010,
2:1005–1017.
34. Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP, Avendano M, Hirsch
S: Effects of vitamin D supplementation and exercise training on
physical performance in Chilean vitamin D deficient elderly subjects. Exp
Gerontol 2006, 41:746–752.
35. Kukuljan S, Nowson CA, Sanders K, Daly RM: Effects of resistance exercise
and fortified milk on skeletal muscle mass, muscle size, and functional
performance in middle-aged and older men: an 18-mo randomized
controlled trial. J Appl Physiol 2009, 107:1864–1873.
36. Ceglia L, da Silva MM, Park LK, Morris E, Harris SS, Bischoff-Ferrari HA,
Fielding RA, Wson-Hughes B: Multi-step immunofluorescent analysis of
vitamin D receptor loci and myosin heavy chain isoforms in human
skeletal muscle. J Mol Histol 2010, 41:137–142.
37. Boland R: Role of vitamin D in skeletal muscle function. Endocr Rev 1986,
7:434–448.
38. Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S,
Busquets X: Skeletal muscle apoptosis and weight loss in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2002,
166:485–489.
39. Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sanchez F, Gea J,
Barbera JA: Cigarette smoke-induced oxidative stress: A role in chronic
obstructive pulmonary disease skeletal muscle dysfunction. Am J Respir
Crit Care Med 2010, 182:477–488.
40. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, LeBlanc
P, Maltais F: Muscle atrophy and hypertrophy signaling in patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007,
176:261–269.
41. Whittom F, Jobin J, Simard PM, LeBlanc P, Simard C, Bernard S, Belleau R,
Maltais F: Histochemical and morphological characteristics of the vastus
lateralis muscle in patients with chronic obstructive pulmonary disease.
Med Sci Sports Exerc 1998, 30:1467–1474.
42. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M:
Vitamin D beyond bones in chronic obstructive pulmonary disease: time
to act. Am J Respir Crit Care Med 2009, 179:630–636.
doi:10.1186/1465-9921-13-84
Cite this article as: Hornikx et al.: Vitamin D supplementation during
rehabilitation in COPD: a secondary analysis of a randomized trial.
Respiratory Research 2012 13:84.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
